# Wake Robin Validation Comparison Report

*Generated: 2026-01-13 17:44:48*

---

## Enhancement: Clinical Coverage Expansion
- **Baseline**: 13% clinical coverage (41/316 tickers)
- **Enhanced**: 75%+ clinical coverage (238/316 tickers)
- **Method**: Expanded ticker -> sponsor name mapping

## Validation Status

- **Total Test Periods**: 7
- **Baseline Complete**: 7 [DONE]
- **Enhanced Complete**: 1
- **Pending**: 6

### Quarters Pending Re-validation:
- [ ] 2023-Q2 (2023-04-15)
- [ ] 2023-Q3 (2023-07-15)
- [ ] 2023-Q4 (2023-10-15)
- [ ] 2024-Q1 (2024-01-15)
- [ ] 2024-Q2 (2024-04-15)
- [ ] 2024-Q3 (2024-07-15)

## Quarter-by-Quarter Comparison

| Quarter | Screen Date | Q1-Q5 Spread (Before) | Q1-Q5 Spread (After) | Change | Q1 Alpha (Before) | Q1 Alpha (After) | Change |
|---------|-------------|------------------------|----------------------|--------|-------------------|------------------|--------|
| 2023-Q1 | 2023-01-15 | +8.66% | +13.60% | [UP] +4.94% | +12.18% | +16.81% | [UP] +4.63% |
| 2023-Q2 | 2023-04-15 | +3.79% | *pending* | - | +7.66% | *pending* | - |
| 2023-Q3 | 2023-07-15 | +12.97% | *pending* | - | +5.29% | *pending* | - |
| 2023-Q4 | 2023-10-15 | +18.43% | *pending* | - | +12.58% | *pending* | - |
| 2024-Q1 | 2024-01-15 | +13.19% | *pending* | - | +19.21% | *pending* | - |
| 2024-Q2 | 2024-04-15 | -14.53% | *pending* | - | -2.54% | *pending* | - |
| 2024-Q3 | 2024-07-15 | +22.62% | *pending* | - | +29.57% | *pending* | - |

## Aggregate Performance

### Average Q1-Q5 Spread
- **Before**: +9.30%
- **After**: +13.60%
- **Improvement**: +4.30% (+46.2%)

### Average Alpha
- **Before**: +11.99%
- **After**: +16.81%
- **Improvement**: +4.82% (+40.2%)

### Success Rate (Positive Spreads)
- **Before**: 6/7 (85.7%)
- **After**: 1/1 (100.0%)

## Improvements by Quarter

### Q1-Q5 Spread Changes:
- **2023-Q1**: +8.66% -> +13.60% (*+4.94% improved*)